John Dawson is stepping down as CEO, while current chairman Dr Roch Doliveux will become interim CEO. Dawson will remain a board director and advisor to the company, and a process to appoint a new CEO is underway. Oxford Biomedica will acquire an 80% interest in the new business for a US$130mln cash consideration payable to Homology and a US$50mln capital injection into Oxford Biomedia Solutions to fund growth. Homology will retain a 20% stake in the new business.